Rocket Pharmaceuticals, Inc. (RCKT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Rocket Pharmaceuticals, Inc. (RCKT) is down 1.4% since the beginning of the year. At $3 per share, RCKT is trading 36.5% below its 52-week high of $5. Investors who bought $1,000 worth of RCKT shares 5 years ago would now be looking at an investment worth $80.

Rocket Pharmaceuticals, Inc. (RCKT) has returned -1.42% so far this year and 28.15% over the past 12 months. Over the last ten years, RCKT has returned -19.15% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Feb 18, 2015, RCKT's average daily return is +0.11%, while the average monthly return is +1.66%. At this rate, an investment would double in approximately 3.5 years.

Historically, 50% of months were positive and 50% were negative. The best month was Jul 2015 with a return of +165.1%, while the worst month was Jan 2017 at -73.8%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 8 months.

On a daily basis, RCKT closed higher 48% of trading days. The best single day was Jul 23, 2015 with a return of +193.9%, while the worst single day was Jan 3, 2017 at -71.3%.

Rocket Pharmaceuticals, Inc. has an annualized alpha of 9.33%, beta of 1.44, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since February 18, 2015.

• This stock participated in 175.24% of S&P 500 Index downside but only 59.31% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

RCKT ranks 56 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Rocket Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Rocket Pharmaceuticals, Inc. was 96.70%, occurring on May 27, 2025. The portfolio has not yet recovered.

The current Rocket Pharmaceuticals, Inc. drawdown is 95.10%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Rocket Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Rocket Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.